BLOG Archives | Page 6 of 6 | MicroGen Diagnostics

March 30, 2026

Why Molecular Diagnostic Claims Get Denied – And What That Means for Your Patients

Understanding the gap between clinical necessity and insurance coverage — and how your billing team can help close it. The Test Was Right. The Claim Was Denied. You ordered a molecular diagnostic test because culture alone wasn’t giving you the answer you needed. The clinical rationale was sound. The result informed your treatment plan. And then the claim came back denied. This scenario is more common than it should be — and it rarely has anything to do with whether the test was medically necessary. More often, the denial stems from a mismatch between how the encounter was documented and […]

April 15, 2026

Inside the Lab: The Unseen Commitment to Quality at MicroGenDX

In Sequence: The Unseen Commitment to Quality at MicroGenDX When you receive your test results from MicroGenDX, you are seeing the final product of a comprehensive lab quality journey that began long before your sample arrived at our laboratory. What you don’t see are the countless hours of validation, the daily quality checks, the rigorous training programs, and the unwavering commitment to accuracy that happens behind our laboratory doors. Let’s pull back the curtain and show you what really goes on in our lab. The Foundation: Test Validation and Development Before any of our tests are approved for real world […]

June 4, 2026

Synovial NGS Concordance with ICM Criteria for PJI Diagnosis

Synovial NGS Concordance with ICM Criteria for PJI Diagnosis Periprosthetic joint infection (PJI) is one of the most consequential complications of hip and knee arthroplasty, and it is also one of the hardest to confirm. No single test settles the question on its own. The International Consensus Meeting 2018 (ICM-18) definition addresses this by combining major and minor criteria, yet major criteria such as two phenotypically matching positive cultures or a sinus tract communicating with the joint are not met in up to 29 percent of cases (Sigmund et al., 2022). Culture-negative PJI compounds the problem, occurring in roughly 28 […]